Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 03:11PM ET
1.78
Dollar change
+0.08
Percentage change
4.71
%
Index- P/E- EPS (ttm)-12.91 Insider Own9.27% Shs Outstand3.07M Perf Week-11.88%
Market Cap5.46M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.78M Perf Month-18.35%
Income-14.46M PEG- EPS next Q-0.70 Inst Own2.96% Short Float16.27% Perf Quarter33.33%
Sales0.13M P/S42.04 EPS this Y90.30% Inst Trans8.22% Short Ratio4.42 Perf Half Y-28.51%
Book/sh0.84 P/B2.12 EPS next Y- ROA-281.29% Short Interest0.45M Perf Year-75.73%
Cash/sh0.98 P/C1.81 EPS next 5Y- ROE-1080.24% 52W Range1.08 - 26.40 Perf YTD2.30%
Dividend Est.- P/FCF- EPS past 5Y74.20% ROI-538.83% 52W High-93.26% Beta0.63
Dividend TTM- Quick Ratio1.74 Sales past 5Y-37.47% Gross Margin40.17% 52W Low64.81% ATR (14)0.15
Dividend Ex-Date- Current Ratio1.74 EPS Y/Y TTM90.51% Oper. Margin-11052.44% RSI (14)43.90 Volatility7.63% 7.73%
Employees12 Debt/Eq0.07 Sales Y/Y TTM-49.81% Profit Margin-11193.30% Recom1.00 Target Price12.50
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q98.25% Payout- Rel Volume0.15 Prev Close1.70
Sales Surprise-54.55% EPS Surprise50.40% Sales Q/Q-50.00% EarningsFeb 14 BMO Avg Volume102.36K Price1.78
SMA20-9.29% SMA50-3.71% SMA200-45.06% Trades Volume13,844 Change4.71%
Mar-19-24 07:30AM
Mar-11-24 07:30AM
Feb-29-24 04:05PM
Feb-14-24 07:30AM
Dec-21-23 08:00AM
04:15PM Loading…
Dec-14-23 04:15PM
Oct-31-23 07:30AM
Oct-25-23 07:30AM
Oct-17-23 08:00AM
Sep-20-23 07:30AM
Sep-19-23 08:30AM
Aug-31-23 10:55AM
Aug-16-23 07:30AM
Aug-14-23 08:00AM
Jul-31-23 09:00AM
08:00AM Loading…
Jun-28-23 08:00AM
Jun-23-23 08:00AM
Jun-20-23 08:00AM
May-10-23 07:30AM
Apr-18-23 04:01PM
Apr-17-23 08:00AM
Mar-14-23 04:31PM
Feb-13-23 08:00AM
Feb-08-23 08:00AM
Feb-01-23 08:00AM
Jan-19-23 08:00AM
Jan-09-23 08:00AM
Dec-15-22 04:05PM
Nov-02-22 08:00AM
Nov-01-22 04:05PM
07:30AM Loading…
Oct-31-22 07:30AM
Oct-04-22 08:00AM
Sep-26-22 08:00AM
Sep-21-22 08:00AM
Sep-16-22 08:30AM
Aug-15-22 04:05PM
Jul-22-22 07:00AM
Jul-21-22 07:30AM
Jun-09-22 07:00AM
Jun-02-22 09:25AM
May-10-22 08:15AM
Apr-13-22 07:00AM
Apr-08-22 01:05PM
Mar-16-22 07:00AM
Feb-09-22 06:30AM
Feb-08-22 07:00AM
Dec-20-21 12:58PM
Dec-17-21 06:30AM
Aug-30-21 04:01PM
Aug-19-21 09:35PM
Aug-16-21 06:30AM
Jun-14-21 07:45AM
Jun-08-21 04:30PM
May-17-21 07:00AM
May-10-21 06:30AM
May-03-21 06:00AM
Mar-29-21 04:30PM
Mar-22-21 07:00AM
Feb-16-21 08:10AM
Feb-03-21 06:30AM
Feb-01-21 06:30AM
Jan-25-21 06:30AM
Dec-17-20 06:30AM
Nov-30-20 08:30AM
Sep-01-20 08:30AM
Aug-25-20 07:30AM
Aug-24-20 07:37AM
Aug-14-20 07:30AM
Aug-04-20 07:35AM
07:30AM
Jul-20-20 07:30AM
Jul-15-20 07:30AM
May-18-20 07:30AM
Apr-06-20 07:30AM
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dexter SusanChief Technical OfficerJun 14 '23Buy0.7010,0007,00033,667Jun 15 04:15 PM
Dyrness Albert D.DirectorMay 30 '23Buy0.4723,25510,88328,962May 31 08:30 AM
Bhatt NaileshDirectorMay 17 '23Buy0.2325,0005,80030,733May 18 08:00 AM
Mohan PankajChairman, President and CEOMay 15 '23Buy0.22371,60082,867553,331May 15 05:17 PM